Autocrine motility factor modulates EGF-mediated invasion signaling

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2229-2237

  Kho, Dhong Hyo ^a   Zhang, Tianpeng ^a   Balan, Vitaly ^a   Wang, Yi ^a   Ha, Seung Wook ^a   Xie, Youming ^a   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASEIN KINASE II; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GLUCOSE 6 PHOSPHATE ISOMERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOCHROME P-450 ENZYME SYSTEM; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCOSE-6-PHOSPHATE ISOMERASE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84899517033     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2937     Document Type: Article

References (33)

1. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996;56:2960-3.
2. Gurney ME. Neuroleukin: basic biology and functional interaction with human immunodeficiency virus. Immunol Rev 1987;100:203-23.
3. Xu W, Seiter K, Feldman E, Ahmed T, Chiao JW. The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood 1996;87: 4502-6.
4. Fairbank M, St-Pierre P, Nabi IR. The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase. Mol Biosyst 2009;5:793-801.
5. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 1999;189:1783-9.
6. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 1998;280:85-102.
7. Schwertassek U, Balmer Y, Gutscher M, Weingarten L, Preuss M, Engelhard J, et al. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. EMBO J 2007;26:3086-97.
8. Schwartz V, Kruttgen A, Weis J, Weber C, Ostendorf T, Lue H, et al. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. Eur J Cell Biol 2012;91:435-49.
9. Nabi IR, Watanabe H, Raz A. Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res 1990;50:409-14.
10. Kho DH, Nangia-Makker P, Balan V, Hogan V, Tait L, Wang Y, et al. Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Cancer Res 2013;73:1411-9.
11. Suzuki T, Muraki Y, Yasukochi T, Zhang H, Kori Y, Wakamatsu E, et al. Immunoglobulin G from anti-glucose-6-phosphate isomerase antibodies positive patient with rheumatoid arthritis induces synovitis in cynomolgus monkeys. Autoimmun Rev 2005;4:475-8.
12. Funasaka T, Hogan V, Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res 2009;69:5349-56.
13. Funasaka T, Hu A, Yanagawa T, Hogan V, Raz A. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal- to-epithelial transition of human lung fibrosarcoma cells. Cancer Res 2007;67:4236-43.
14. Polacheck WJ, Zervantonakis IK, Kamm RD. Tumor cell migration in complex microenvironments. Cell Mol Life Sci 2013;70:1335-56.
15. Craene BD, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.
16. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
17. Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S. EGFRtargeted therapy. Exp Cell Res 2011;317:2765-71.
18. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
19. Yanagawa T, Funasaka T, Tsutsumi S, Raz T, Tanaka N, Raz A. Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation. J Biol Chem 2005;280:10419-26.
20. Lee JH, Bae JA, Seo YW, Kho DH, Sun EG, Lee SE, et al. Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9/CD82 and suppresses the Wnt/b-catenin signal via ISGylation of b-catenin. Gut 2010;59:907-17.
21. Kho DH, Bae JA, Lee JH, Cho HJ, Cho SH, Seo YW, et al. KITENIN recruits Dishevelled/PKCd to form a functional complex and controls the migration and invasiveness of colorectal cancer cells. Gut 2009;58:509-19.
22. Tsutsumi S, Gupta SK, Hogan V, Tanaka N, Nakamura KT, Nabi IR, et al. The enzymatic activity of phosphoglucose isomerase is not required for its cytokine function. FEBS Lett 2003;534:49-53.
23. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, b-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009;28:151-66.
24. Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB. Deciphering AP- 1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle 2007;6:2633-9.
25. Hu T, Li C. Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer 2010;9:236.
26. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33.
27. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012;12:553-63.
28. Haga A, Niinaka Y, Raz A. Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein. Biochim Biophys Acta 2000;1480:235-44.
29. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003;369:1-15.
30. Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A. PI3K/ Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 2010;22:1369-78.
31. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene 2005;24:7443-54.
32. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009;69:7135-9.
33. Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol 2005;2: 554-61.